接受单克隆抗体治疗的胃癌患者中 FcR 多态性导致 ADCC 活性增强-猫眼课题宝

接受单克隆抗体治疗的胃癌患者中 FcR 多态性导致 ADCC 活性增强

批准号：

23591934

负责人：

YOSHINO Shigefumi

金额：

$3.16万

依托单位：

Yamaguchi University

依托单位国家：

日本

项目类别：

Grant-in-Aid for Scientific Research (C)

财政年份：

2011

资助国家：

日本

项目状态：

已结题

起止时间：

2011 至 2013

来源：

https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591934/

关键词：

胃癌大腸癌 ADCC活性抗体医薬 Fc受容体遺伝子多型レンチナン

项目摘要

项目成果

YOSHINO Shigefumi的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Monoclonal antibodies are widely used for patients with gastric or colorectal cancer. These drugs have direct effect on the tumor cells, however modulation of the immune response could be another important mechanism. Antibody dependent cellular cytotoxicity (ADCC) mediated through the receptor (FcR) of the antibodies carried by immune cells plays an important role in the antitumor effect of the antibody. In this study, we confirmed that both monoclonal antibodies of trastuzumab and cetuximab had ADCC activity, however immunomodulator lentinan showed no augmentation of ADCC. Genetic features of FcR polymorphisms may be associated with the outcome of cancer patients treated with monoclonal antibodies.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文